Zipradon20 mg

Zipradon is an atypical antipsychotic. Its FDA-approved and evidence-supported uses include:

Established / FDA-approved uses

• Schizophrenia - for the acute and maintenance treatment of schizophrenia in adults.
• Bipolar I disorder, acute manic or mixed episodes - for acute treatment, with or without psychotic features, in adults, as monotherapy.
• Bipolar I disorder, maintenance treatment - as an adjunct to lithium or valproate in adults.
• Acute agitation in schizophrenia - the intramuscular (injectable) form of Zipradon is approved for rapid control of acute agitation in adults with schizophrenia, for a maximum of three consecutive days, after which oral therapy should be substituted if continued treatment is needed.

Off-label / other uses

Zipradon is occasionally used off-label, based on limited evidence, for adjunctive management of other psychiatric conditions; such use should be individualized by a physician and is not FDA-approved.

Zipradon is not approved for the treatment of dementia-related psychosis in elderly patients (see Precautions and Warnings for the boxed warning on increased mortality in this population).

Each oral capsule of Ziprasidone contains Ziprasidone (as ziprasidone hydrochloride) as the active ingredient, available in strengths such as 20 mg, 40 mg, 60 mg, and 80 mg. The intramuscular injection form contains Ziprasidone (as ziprasidone mesylate) as a sterile lyophilized powder for reconstitution, together with sulfobutylether beta-cyclodextrin sodium as a solubilizing excipient.

Zipradon is a second-generation (atypical) antipsychotic medicine belonging to the benzisothiazolyl piperazine chemical class. It is used to manage symptoms of schizophrenia and bipolar I disorder by altering the activity of certain neurotransmitters in the brain, primarily dopamine and serotonin.

Zipradon is available as oral capsules for regular daily use and as an intramuscular injection for short-term management of acute agitation in a hospital or clinical setting.

Atypical (second-generation) antipsychotic; benzisothiazolyl piperazine derivative.

Mechanism of action: Ziprasidone exerts its therapeutic effect primarily through antagonism of dopamine D2 receptors and serotonin 5-HT2A receptors in the brain, a combination believed to reduce psychotic symptoms while lowering the risk of extrapyramidal side effects compared with older, typical antipsychotics.

Ziprasidone also has high affinity for 5-HT2C, 5-HT1D, and 5-HT1A (partial agonist) receptors, and moderate affinity for histamine H1 and alpha-1 adrenergic receptors, and it inhibits synaptic reuptake of serotonin and norepinephrine.

Pharmacokinetics: Oral bioavailability of Ziprasidone increases substantially (roughly two-fold) when taken with food, so it must be taken with a meal for adequate absorption. It is extensively metabolized in the liver, mainly via aldehyde oxidase with a minor contribution from CYP3A4, and has an elimination half-life of approximately 7 hours, supporting twice-daily oral dosing.

Zipradon capsules should be swallowed whole with water and taken with food, since absorption is markedly reduced without food. The intramuscular injection of Zipradon is administered only by a healthcare professional in a clinical setting and must not be given intravenously; see Reconstitution for preparation of the injectable form.

QT-prolonging drugs: Concomitant use of Zipradon with other drugs known to prolong the QT interval (e.g., dofetilide, sotalol, quinidine and other Class Ia/III antiarrhythmics, thioridazine, chlorpromazine, moxifloxacin, pimozide, mefloquine) is contraindicated due to an increased risk of serious ventricular arrhythmias, including torsades de pointes (see Contraindications).

CYP3A4 inhibitors (e.g., ketoconazole): May increase Zipradon plasma concentrations; caution advised.

CYP3A4 inducers (e.g., carbamazepine): May decrease Zipradon plasma concentrations, potentially reducing efficacy.

CNS depressants (alcohol, sedatives, opioids): Additive sedative effects when combined with Zipradon; avoid or use with caution.

Antihypertensive agents: Zipradon may enhance the hypotensive effect, increasing the risk of orthostatic hypotension.

Dopamine agonists/levodopa: Zipradon may antagonize their effects due to its dopamine-receptor blocking activity.

Common: Somnolence/sedation, headache, nausea, constipation, dizziness, akathisia (restlessness), extrapyramidal symptoms (tremor, rigidity), dyspepsia, and respiratory tract infection are reported with Zipradon.

Less common but clinically important: Orthostatic hypotension, weight gain, and metabolic changes such as elevated blood glucose or lipids (see Precautions and Warnings).

Rare but serious: QT-interval prolongation and torsades de pointes, neuroleptic malignant syndrome, tardive dyskinesia, seizures, priapism, and allergic reactions including rash and, rarely, severe skin reactions.

Patients taking Zipradon should seek prompt medical attention for palpitations, fainting, high fever with muscle rigidity, uncontrolled muscle movements, or signs of an allergic reaction.

Pregnancy: Data on Zipradon use in pregnancy are limited. Neonates exposed to antipsychotics, including Zipradon, during the third trimester are at risk of extrapyramidal and/or withdrawal symptoms after delivery. Zipradon should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under the direct supervision of a physician.

Lactation: It is not known whether Zipradon passes into human breast milk in clinically significant amounts. Because of the potential for adverse effects in a nursing infant, a decision to discontinue breastfeeding or discontinue Zipradon should be made only after consulting a physician, taking into account the importance of treatment to the mother.

Boxed Warning - Increased mortality in elderly patients with dementia-related psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including Zipradon, are at increased risk of death compared with placebo. Zipradon is not approved for the treatment of dementia-related psychosis.

QT prolongation: Zipradon can prolong the QT interval in a dose-related manner, which may increase the risk of life-threatening arrhythmias. Baseline and periodic ECG monitoring should be considered, especially with cardiac risk factors, electrolyte abnormalities, or concurrent QT-prolonging drugs. Hypokalemia and hypomagnesemia should be corrected before and during treatment.

Neuroleptic malignant syndrome (NMS): A rare but potentially fatal reaction presenting with hyperthermia, muscle rigidity, altered mental status, and autonomic instability. Zipradon should be discontinued immediately if NMS is suspected.

Metabolic changes: Weight gain, dyslipidemia, and hyperglycemia have been reported. Zipradon is generally considered to have a comparatively favorable metabolic profile among atypical antipsychotics, but periodic monitoring of weight, blood glucose, and lipids is still recommended.

Tardive dyskinesia: Long-term use of Zipradon may cause potentially irreversible, involuntary movements; risk increases with duration of treatment and cumulative dose.

Orthostatic hypotension: Use with caution in patients with cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension.

Administration requirement: Zipradon must be taken with food, as bioavailability is significantly reduced when taken on an empty stomach.

Other precautions: Leukopenia/neutropenia/agranulocytosis, seizures, cognitive and motor impairment (caution when driving or operating machinery), difficulty swallowing (dysphagia), body temperature dysregulation, and increased suicidal thoughts in some patients, particularly early in treatment.

Overdose with Zipradon may cause sedation, slurred speech, elevated blood pressure, and QT-interval prolongation, which can lead to life-threatening arrhythmias.

There is no specific antidote for Zipradon overdose. Anyone suspected of having taken an overdose of Zipradon should seek immediate medical attention or contact emergency services or poison control. Management in a hospital setting typically involves cardiac (ECG) monitoring and supportive care; overdose should never be treated at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. The reconstituted intramuscular injection of Zipradon should be used promptly and stored as directed by the manufacturer and a healthcare professional.

Elderly: Zipradon is not approved for dementia-related psychosis due to increased mortality risk (see Precautions and Warnings). Use with caution in elderly patients due to increased susceptibility to orthostatic hypotension and sedation.

Pediatric: Safety and efficacy of Zipradon have not been established in patients under 18 years of age (see Pediatric Uses).

Renal impairment: No dosage adjustment needed for oral Zipradon; the intramuscular formulation should be used cautiously (see Dosage and Administration).

Hepatic impairment: Use Zipradon with caution; lower doses may be needed.

Pregnancy and lactation: See Pregnancy and Lactation section.

The duration of treatment with Zipradon should be determined by a physician based on individual response, and may range from weeks (for the acute phase of mania) to months or years (for maintenance therapy in schizophrenia or bipolar I disorder). Periodic reassessment is recommended to confirm the continued need for treatment. The intramuscular injection form of Zipradon is intended for short-term use only, up to a maximum of 3 consecutive days.

The intramuscular injection form of Zipradon (Zipradon mesylate for injection) is supplied as a sterile lyophilized powder that must be reconstituted by a healthcare professional immediately before use. It is reconstituted by adding 1.2 mL of Sterile Water for Injection to the vial and shaking vigorously until fully dissolved, yielding a solution containing 20 mg/mL of Zipradon. The reconstituted solution should be inspected for particulate matter and discoloration before administration and used promptly, or stored under refrigeration and used within the timeframe specified by the manufacturer if not used immediately. Oral Zipradon capsules do not require reconstitution.

Atypical (second-generation) antipsychotic; benzisothiazolyl piperazine derivative.

Ziprasidone works mainly by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain, which helps reduce hallucinations, delusions, and mood symptoms associated with schizophrenia and bipolar I disorder. See Pharmacology for full mechanistic detail.

C

The safety and efficacy of Zipradon have not been established in patients younger than 18 years of age for schizophrenia or bipolar I disorder. Zipradon is therefore not routinely recommended in children and adolescents, and should only be considered in this age group if a physician determines the potential benefit outweighs the risks, with close monitoring for QT prolongation, metabolic effects, and behavioral changes.